Oxygenta Pharma

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE102E01018
NSEID:
BSEID: 524636

INR

55.00

0.00 (0.00%)

BSENSE

Dec 17

BSE+NSE Vol: 4.41 k

{
  "main_header": {
    "sid": 798135,
    "name": "Oxygenta Pharma",
    "stock_name": "Oxygenta Pharma",
    "full_name": "Oxygenta Pharmaceutical Ltd",
    "name_url": "stocks-analysis/oxygenta-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "55.00",
    "chg": "0.00",
    "chgp": "0.00%",
    "dir": 0,
    "prev_price": "55.00",
    "mcapval": "197.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524636,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE102E01018",
    "curr_date": "Dec 17",
    "curr_time": "",
    "bse_nse_vol": "4.41 k",
    "exc_status": "Active",
    "traded_date": "Dec 17, 2025",
    "traded_date_str": "2025 12 17",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/oxygenta-pharma-798135-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Oxygenta Pharmaceutical Stock Hits 52-Week Low at Rs.52.1 Amidst Market Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/oxygenta-pharmaceutical-stock-hits-52-week-low-amidst-continued-decline-3760142",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/OxygentaPharmac_priceRelatedfactors_3760142.png",
        "date": "2025-12-16 12:21:16",
        "description": "Oxygenta Pharmaceutical has reached a new 52-week low of Rs.52.1, marking a significant decline in its stock price amid a broader market downturn. The stock has underperformed its sector and the benchmark indices, reflecting ongoing challenges within the company and the pharmaceuticals sector."
      },
      {
        "title": "Why is Oxygenta Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-oxygenta-pharma-fallingrising-3759140",
        "imagepath": "",
        "date": "2025-12-16 00:48:22",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Context</strong></p>\n<p>Oxygenta Pharma’s share price has been under pressure over the past week, falling by 6.60% compared to a marginal 0.13% gain in the Sensex. The one-month performance further emphasises this trend, with the stock declining 8.58% while the Sensex rose by 0.77%. Year-to-date, the stock has suffered a steep 36.42% loss, in stark contrast to the Sensex’s 9.05% gain. Over the last year, the stock’s decline of 38.32% is again at odds with the Sensex’s positive 3.75% return. These figures highlight a persistent underperformance relative to the benchmark index.</p>\n<p>Despite this recent weakness, it is notable that over longer horizons, Oxygenta Pharma has delivered substantial gains. The three-year return stands at an impressive 119.80%, sign..."
      },
      {
        "title": "Oxygenta Pharma’s Evaluation Revised Amidst Challenging Financial and Market Conditions",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/oxygenta-pharma-downgraded-to-strong-sell-amid-deteriorating-fundamentals-3744024",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/OxygentaPharma_mojoScore_3744024.png",
        "date": "2025-12-03 11:08:14",
        "description": "Oxygenta Pharma has experienced a revision in its market evaluation, reflecting shifts in its financial performance and market positioning. This adjustment highlights ongoing challenges within the Pharmaceuticals & Biotechnology sector, particularly for microcap companies facing operational and valuation pressures."
      },
      {
        "title": "Oxygenta Pharmaceutical Sees Extraordinary Buying Interest Amid Upper Circuit Scenario",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/oxygenta-pharmaceutical-hits-upper-circuit-amidst-unprecedented-buying-interest-3720527",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/OxygentaPharmac_only_buyers_3720527.png",
        "date": "2025-11-21 10:10:38",
        "description": "Oxygenta Pharmaceutical has attracted remarkable buying interest today, with the stock hitting an upper circuit and registering only buy orders in the queue. This unusual market behaviour signals a potential multi-day circuit scenario, reflecting strong demand despite recent price pressures and sector trends."
      },
      {
        "title": "Oxygenta Pharmaceutical Ltd Surges 5% Today, Reaching Intraday High of Rs 63.87",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/oxygenta-pharmaceutical-ltd-surges-5-today-reaching-intraday-high-of-rs-6387-3706847",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/OxygentaPharmac_only_buyers_3706847.png",
        "date": "2025-11-17 10:20:39",
        "description": "Oxygenta Pharmaceutical Ltd is experiencing notable buying activity, with a significant stock increase today, reversing a two-day decline. Despite recent challenges, the stock has shown impressive long-term growth over five years. Current performance metrics indicate mixed technical signals, reflecting ongoing market sentiment and potential sector developments."
      },
      {
        "title": "Oxygenta Pharmaceutical Ltd Surges 4.99% Today, Reaching Intraday High of Rs 63.99",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/oxygenta-pharmaceutical-ltd-surges-499-today-reaching-intraday-high-of-rs-6399-3701019",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/OxygentaPharmac_only_buyers_3701019.png",
        "date": "2025-11-14 10:00:36",
        "description": "Oxygenta Pharmaceutical Ltd is experiencing notable buying activity, with the stock rising significantly today, in contrast to a decline in the Sensex. Despite recent challenges, the stock has shown resilience over the past month, outperforming the index, while current trading indicates mixed trends in the short to medium term."
      },
      {
        "title": "Why is Oxygenta Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-oxygenta-pharma-fallingrising-3687134",
        "imagepath": "",
        "date": "2025-11-10 23:00:10",
        "description": "As of 10-Nov, Oxygenta Pharmaceutical Ltd is experiencing a decline in its stock price, currently at Rs 62.40, which reflects a decrease of Rs 2.07 or 3.21%. The stock has been underperforming, having lost 6.64% over the last two days and is currently trading below its recent moving averages, specifically lower than the 5-day, 50-day, 100-day, and 200-day moving averages. Additionally, the stock has underperformed its sector by 4.26% today. In terms of returns, over the past week, the stock has decreased by 3.81%, while it has shown a significant decline of 28.66% year-to-date and 29.76% over the past year, despite a strong performance over the last three and five years.\n\nBroader Market Context: In comparison to the benchmark Sensex, which has only decreased by 0.53% over the past week, Oxygenta's short-term performance is notably weaker. The Sensex has shown a positive return of 1.25% over the past month, ..."
      },
      {
        "title": "Oxygenta Pharmaceutical Ltd Faces Significant Selling Pressure with 35.03% Decline Over Three Months",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/oxygenta-pharmaceutical-ltd-faces-significant-selling-pressure-with-3503-decline-over-three-months-3684736",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/OxygentaPharmac_only_sellers_3684736.png",
        "date": "2025-11-10 09:31:43",
        "description": "Oxygenta Pharmaceutical Ltd is experiencing significant selling pressure, with consecutive losses leading to an 8.29% decline over two days. The stock has underperformed against the Sensex, showing a 35.03% drop over the past three months and trading below key moving averages, indicating ongoing challenges in the market."
      },
      {
        "title": "How has been the historical performance of Oxygenta Pharma?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-oxygenta-pharma-3683561",
        "imagepath": "",
        "date": "2025-11-09 22:42:18",
        "description": "Answer:\nThe historical performance of Oxygenta Pharma shows significant fluctuations in its financial metrics over the years, with a notable increase in net sales in March 2025 reaching 109.30 Cr, up from 39.64 Cr in March 2024 and 30.99 Cr in March 2023. However, the company has faced challenges with total expenditure, which rose to 119.30 Cr in March 2025 from 49.34 Cr in March 2024, leading to an operating profit of -10.00 Cr in March 2025, slightly worse than -9.70 Cr in the previous year. The profit before tax also declined to -14.35 Cr in March 2025 from -13.87 Cr in March 2024, while the profit after tax was -10.30 Cr, worsening from -3.48 Cr in March 2024. The company's total liabilities increased to 72.62 Cr in March 2025 from 54.46 Cr in March 2024, with total debt at 62.23 Cr. Shareholder's funds remained negative at -25.02 Cr in March 2025, indicating ongoing financial distress. Cash flow from o..."
      }
    ],
    "total": 207,
    "sid": "798135",
    "stock_news_url": "https://www.marketsmojo.com/news/oxygenta-pharmaceutical-798135"
  },
  "announcements": [
    {
      "caption": "Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot",
      "datetime": "11-Dec-2025",
      "details": "Outcome of the Postal Ballot",
      "source": "BSE"
    },
    {
      "caption": "Minutes Of The Resolutions Passed By Way Of Postal Ballot",
      "datetime": "11-Dec-2025",
      "details": "Minutes of the resolution passed by way Postal Ballot",
      "source": "BSE"
    },
    {
      "caption": "Intimation Under Regulation 30 The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 As Amended (SEBI Listing Regulations) To Stock Exchanges Regarding Approval Of The Shareholders For Reclassification Of Person(S) Forming Part Of Th",
      "datetime": "11-Dec-2025",
      "details": "Reclassification of promoters to public",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Oxygenta Pharmaceutical Stock Hits 52-Week Low at Rs.52.1 Amidst Market Pressure

2025-12-16 12:21:16

Oxygenta Pharmaceutical has reached a new 52-week low of Rs.52.1, marking a significant decline in its stock price amid a broader market downturn. The stock has underperformed its sector and the benchmark indices, reflecting ongoing challenges within the company and the pharmaceuticals sector.

Why is Oxygenta Pharma falling/rising?

2025-12-16 00:48:22

Recent Price Movement and Market Context

Oxygenta Pharma’s share price has been under pressure over the past week, falling by 6.60% compared to a marginal 0.13% gain in the Sensex. The one-month performance further emphasises this trend, with the stock declining 8.58% while the Sensex rose by 0.77%. Year-to-date, the stock has suffered a steep 36.42% loss, in stark contrast to the Sensex’s 9.05% gain. Over the last year, the stock’s decline of 38.32% is again at odds with the Sensex’s positive 3.75% return. These figures highlight a persistent underperformance relative to the benchmark index.

Despite this recent weakness, it is notable that over longer horizons, Oxygenta Pharma has delivered substantial gains. The three-year return stands at an impressive 119.80%, sign...

Oxygenta Pharma’s Evaluation Revised Amidst Challenging Financial and Market Conditions

2025-12-03 11:08:14

Oxygenta Pharma has experienced a revision in its market evaluation, reflecting shifts in its financial performance and market positioning. This adjustment highlights ongoing challenges within the Pharmaceuticals & Biotechnology sector, particularly for microcap companies facing operational and valuation pressures.

Oxygenta Pharmaceutical Sees Extraordinary Buying Interest Amid Upper Circuit Scenario

2025-11-21 10:10:38

Oxygenta Pharmaceutical has attracted remarkable buying interest today, with the stock hitting an upper circuit and registering only buy orders in the queue. This unusual market behaviour signals a potential multi-day circuit scenario, reflecting strong demand despite recent price pressures and sector trends.

Oxygenta Pharmaceutical Ltd Surges 5% Today, Reaching Intraday High of Rs 63.87

2025-11-17 10:20:39

Oxygenta Pharmaceutical Ltd is experiencing notable buying activity, with a significant stock increase today, reversing a two-day decline. Despite recent challenges, the stock has shown impressive long-term growth over five years. Current performance metrics indicate mixed technical signals, reflecting ongoing market sentiment and potential sector developments.

Oxygenta Pharmaceutical Ltd Surges 4.99% Today, Reaching Intraday High of Rs 63.99

2025-11-14 10:00:36

Oxygenta Pharmaceutical Ltd is experiencing notable buying activity, with the stock rising significantly today, in contrast to a decline in the Sensex. Despite recent challenges, the stock has shown resilience over the past month, outperforming the index, while current trading indicates mixed trends in the short to medium term.

Why is Oxygenta Pharma falling/rising?

2025-11-10 23:00:10

As of 10-Nov, Oxygenta Pharmaceutical Ltd is experiencing a decline in its stock price, currently at Rs 62.40, which reflects a decrease of Rs 2.07 or 3.21%. The stock has been underperforming, having lost 6.64% over the last two days and is currently trading below its recent moving averages, specifically lower than the 5-day, 50-day, 100-day, and 200-day moving averages. Additionally, the stock has underperformed its sector by 4.26% today. In terms of returns, over the past week, the stock has decreased by 3.81%, while it has shown a significant decline of 28.66% year-to-date and 29.76% over the past year, despite a strong performance over the last three and five years. Broader Market Context: In comparison to the benchmark Sensex, which has only decreased by 0.53% over the past week, Oxygenta's short-term performance is notably weaker. The Sensex has shown a positive return of 1.25% over the past month, ...

Oxygenta Pharmaceutical Ltd Faces Significant Selling Pressure with 35.03% Decline Over Three Months

2025-11-10 09:31:43

Oxygenta Pharmaceutical Ltd is experiencing significant selling pressure, with consecutive losses leading to an 8.29% decline over two days. The stock has underperformed against the Sensex, showing a 35.03% drop over the past three months and trading below key moving averages, indicating ongoing challenges in the market.

How has been the historical performance of Oxygenta Pharma?

2025-11-09 22:42:18

Answer: The historical performance of Oxygenta Pharma shows significant fluctuations in its financial metrics over the years, with a notable increase in net sales in March 2025 reaching 109.30 Cr, up from 39.64 Cr in March 2024 and 30.99 Cr in March 2023. However, the company has faced challenges with total expenditure, which rose to 119.30 Cr in March 2025 from 49.34 Cr in March 2024, leading to an operating profit of -10.00 Cr in March 2025, slightly worse than -9.70 Cr in the previous year. The profit before tax also declined to -14.35 Cr in March 2025 from -13.87 Cr in March 2024, while the profit after tax was -10.30 Cr, worsening from -3.48 Cr in March 2024. The company's total liabilities increased to 72.62 Cr in March 2025 from 54.46 Cr in March 2024, with total debt at 62.23 Cr. Shareholder's funds remained negative at -25.02 Cr in March 2025, indicating ongoing financial distress. Cash flow from o...

View All News